Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (51-60 of 156) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 8, 2014
Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancerNami Ueki, Yukinori Matsuo, Yosuke Togashi, et al.
Journal for Immunotherapy of Cancer|October 14, 2018
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8<sup>+</sup> T cells in the tumor microenvironmentYasuko Tada, Yosuke Togashi, Daisuke Kotani, et al.
Oncology Reports|December 18, 2010
Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Lung Cancer (Amsterdam, Netherlands)|March 8, 2011
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Cancer|October 2, 2010
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinomaYosuke Togashi, Katsuhiro Masago, Takeshi Kubo, et al.
Thoracic Cancer|January 20, 2021
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIsSho Watanabe, Yasushi Goto, Hiroyuki Yasuda, et al.
Medical Oncology (Northwood, London, England)|March 20, 2010
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancerKatsuhiro Masago, Shiro Fujita, Tadashi Mio, et al.
Medical Oncology (Northwood, London, England)|December 8, 2010
Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitorKaoru Irisa, Katsuhiro Masago, Yosuke Togashi, et al.
Clinical Lung Cancer|January 29, 2011
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapyKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.
Clinical Lung Cancer|July 22, 2011
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusionKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.
Pageof 16

Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 8, 2014
Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancerNami Ueki, Yukinori Matsuo, Yosuke Togashi, et al.
Journal for Immunotherapy of Cancer|October 14, 2018
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8<sup>+</sup> T cells in the tumor microenvironmentYasuko Tada, Yosuke Togashi, Daisuke Kotani, et al.
Oncology Reports|December 18, 2010
Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Lung Cancer (Amsterdam, Netherlands)|March 8, 2011
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Shiro Fujita, et al.
Cancer|October 2, 2010
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinomaYosuke Togashi, Katsuhiro Masago, Takeshi Kubo, et al.
Thoracic Cancer|January 20, 2021
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIsSho Watanabe, Yasushi Goto, Hiroyuki Yasuda, et al.
Medical Oncology (Northwood, London, England)|March 20, 2010
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancerKatsuhiro Masago, Shiro Fujita, Tadashi Mio, et al.
Medical Oncology (Northwood, London, England)|December 8, 2010
Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitorKaoru Irisa, Katsuhiro Masago, Yosuke Togashi, et al.
Clinical Lung Cancer|January 29, 2011
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapyKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.
Clinical Lung Cancer|July 22, 2011
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusionKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.
Pageof 16